Preparation and Characterization of Estradiol Valerate Microspheres Using Biodegradable Polymers Preparation of estradiol valerate microspheres
Iranian Journal of Pharmaceutical Sciences,
Vol. 2 No. 1 (2006),
15 Dey 2006
,
Page 3-10
https://doi.org/10.22037/ijps.v2.39575
Abstract
In this study, microspheres containing estradiol valerate were prepared by solvent evaporation method using poly (glycolide-co-lactide) (PLGA 50:50) and poly
(lactide). The effect of different process variables such as polymer type, drugpolymer ratio, stirring rate, volume of internal phase and temperature of external
phase on the morphology, particle size distribution, encapsulation efficiency and in vitro release profile were investigated. All microspheres had spherical shape with smooth surface. Increasing the internal phase volume and decreasing the external phase temperature resulted in smaller particles. At low drug loadings, PLGA microspheres were larger than PLA ones. Changing the theoretical drug loading from 5 to 20% decreased the drug release rate from PLGA microspheres whereas the result for PLA microspheres was the opposite.
- Estradiol valerate
- Microspher
- Particulate drug delivery
- Poly lactide
- Poly (lactide-co-glycolide)
- Solvent evaporation
How to Cite
References
[2] Anderso PO, Knoben JE, Troutman WG. Hand book of clinical drug data. 10th edition. New York: Mc Graw-Hill, 2002; p. 679.
[3] Jalil R, Nixon JR. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. J Microencap 1990; 7: 297-325.
[4] Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactid-coglicolide) (PLGA) devices. Biomaterials 2000; 21: 2475-90.
[5] Khuller GK, Dutt M. Sustained release of isoniazid from a single injectable dose of poly (DL-lactid-co-glicolide) microparticles as a therapeutic approach toward tuberculosis. Int J Antimicrob Agents 2001; 17:115-22.
[6] Bulent M, Noyan V, Fener N. Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins and coagulation parameters. Contraception 2001; 63: 151-3.
[7] Kamijo A, Kamei S, Saikawa A, Igari Y, Ogawa Y. In vitro release test system of (lactic-glycolic) acid copolymer microcapsules for sustained release of LHRH agonist (leuprorelin). J Control Rel 1996; 40: 269-76.
[8] Watts PJ, Davies MC, Melia CD. Microencapsulation using emulsification solvent evaporation: An overview of techniques and application. Crit Rev Ther Drug Carrier Syst 1990; 7: 235-59.
[9] Arshady R. Microsphere and microcapsules, a survey of manufacturing technique. I. suspension cross-linking. Polym Eng Sci 1989; 29: 1746-68.
[10] Dinarvand R, Moghadam SH, Mohammadyari-Fard L, Attyabi F. Preparation of biodegradable microspheres and matrix devices containing naltrexone. AAPS Pharm Sci Tech 2003; 4.
[11] Yang Q, Owusu-Ababio G. Biodegradable progestron microsphere delivery systems for osteoporosis therapy. Drug Dev Ind Pharm 2000; 26: 61-70.
[12] Li SM, Garreau H, Vert M. Structure-property relationships in the case of the degradation of massive aliphatic poly (alpha-hydroxy acids) in aqueous media. J Mater Sci Mater Med 1990; 1: 123-30.
[13] Cardinal JR. Matrix systems. In: Langer RS, Wise DL, (editors). Medical applications of controlled release systems. Vol. 1. FL: CRC Press Inc, 1984; pp. 43-4.
- Abstract Viewed: 95 times
- IJPS_Volume 2_Issue 1_Pages 3-10 Downloaded: 19 times